Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy.
- Author:
Hua-qi ZHANG
1
;
Jin-ming YU
;
Xue MENG
;
Jin-bo YUE
;
Rui FENG
;
Li MA
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carcinoma, Non-Small-Cell Lung; diagnostic imaging; metabolism; pathology; therapy; Cisplatin; administration & dosage; Combined Modality Therapy; Female; Fluorodeoxyglucose F18; pharmacokinetics; Humans; Lung Neoplasms; diagnostic imaging; metabolism; pathology; therapy; Male; Middle Aged; Neoplasm Staging; Paclitaxel; administration & dosage; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; pharmacokinetics; Radiotherapy, Conformal; Tomography, X-Ray Computed; Vinblastine; administration & dosage; analogs & derivatives
- From: Chinese Journal of Oncology 2010;32(8):603-606
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the value of (18)F-FDG PET-CT for assessment of therapeutic response and prediction of patient outcome after concurrent chemoradiotherapy (CCRT) of non-small cell lung cancer (NSCLC).
METHODSForty six patients with histologically proven stage III NSCLC had two repeated (18)F-FDG PET-CT scans either one week before therapy and at the dose of 40 ∼ 50 Gy. The SUV(max) and changes of the two groups were compared with (1) the therapeutic response and (2) treatment results and long-term survival.
RESULTSOf the 46 eligible cases, the pretreatment SUV(max) of the responding and non-responding groups was 7.59 ± 3.14 and 14.72 ± 4.67, respectively. The midtreatment SUV(max) of the two groups was 2.89 ± 1.39 and 9.82 ± 3.31, respectively. Significant difference(t = 4.74, P = 0.001;t = 7.23, P = 0.001) in SUV(max) was observed both before and during treatment. Furthermore, the percentage change of pretreatment and midtreatment SUV(max) was ΔSUV(max) = 61.9% ± 8.7% and ΔSUV(max) = 33.6% ± 9.0%, also with a significant difference between the two groups (t = 2.83, P = 0.007). In addition, the 1-year survival rate of the the responding and non-responding groups was 68.0% and 38.1%, respectively. The 2-year survival rate of the two groups was 64.0% and 33.3%, respectively, with a significant difference between the two groups (P = 0.043, P = 0.038).
CONCLUSION(18)F-FDG PET-CT is highly effective in detecting therapeutic response in stage III NSCLC patients. The analysis of percentage change of SUV(max) provides incremental value in early prediction of therapeutic response and patient outcome.
